Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry

Reuters Events 11 - 22 October, 2021, Virtual
Board level executives from Novartis, Bayer and Boehringer Ingelheim, amongst many more, will showcase their long-term visions for healthcare as a response to the COVID-19 pandemic, by joining the speaker faculty at Reuters Events Pharma Europe 2021.

Reuters Events will bring together another 150 life sciences leaders as speakers, and thousands more executive attendees, to showcase the investments being made as the industry accelerates its digital transformation platform to ensure changes are embedded for long-term value for physicians and patients alike.

Blair Gottscho, Managing Director - Pharma, Reuters Events, said the pharma industry had responded well to the challenges of the pandemic, re-assessed operating models, and have found new ways to deliver for physicians, clinicians, providers, payers and patients alike.

"There is significant investment happening across the industry - in both people and technology - to create long-lasting, integrated and flexible systems and processes, that are helping to build a more sustainable healthcare systems.

"We're proud to be showcasing the best and brightest at Pharma Europe 2021. This is the global home for industry executives to set strategy post-pandemic.” Along with this investment, the industry is experiencing an acceleration in collaboration between functions within organizations. However, the environment for collaboration extends beyond company walls, as companies are increasingly forming partnerships that build value for all healthcare stakeholders.

Josh Bramwell, Head of Europe, Reuters Events, said the industry had stepped up to the challenges that the pandemic has created.

“Companies are now seeing collaboration as a competitive advantage," Bramwell said.

"They've looked to optimise pre-competitive opportunities with industry partners, foster long-term stakeholder partnerships to provide real-world patient value, and remove function silos to deliver an agile and efficient business model. These are the case studies that we'll be highlighting on stage at Pharma Europe 2021."

Reuters Events Pharma Europe has been running for 18 years and was previously known as eyeforpharma Barcelona.

You can learn more about Pharma Europe here: https://reutersevents.com/events/barcelona/

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

GSK announces positive Phase IIa study results for…

GSK plc (LSE/NYSE: GSK) announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well t...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Machine learning can help predict patient response…

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...